Walden H. Lee

FDA investigator

Appears on 23 documents from 2013 to 2026, mostly at sites in California. Most often cites testing and release for distribution (21 CFR 211.165).

23
Documents on file
6.5
Observations per 483
2013
First seen
2026
Most recent

What they cite most

From 150 observations

Activity by year

2013: 1, 2015: 1, 2016: 1, 2017: 2, 2018: 1, 2019: 6, 2020: 3, 2021: 2, 2023: 1, 2024: 3, 2026: 2

Where

California 16 · India 2 · Washington 2 · Colorado 1 · Florida 1 · Oklahoma 1

Is Walden H. Lee coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

23 documents, newest first
FirmOpen
483 Jubilant HollisterStier LLCJun 17, 2026 · Spokane, Washington
483 K.C. Pharmaceuticals, Inc.Feb 13, 2026 · Pomona, California
483 Jubilant HollisterStier LLCJun 6, 2024 · Spokane, Washington
483 Polypeptide Laboratories IncMay 10, 2024 · Torrance, California
483 Amphastar Pharmaceuticals, Inc.Mar 1, 2024 · Rancho Cucamonga, California
483 Med-Pharmex, IncDec 18, 2023 · Pomona, California
483 Med-Pharmex, IncSep 14, 2021 · Pomona, California

About this profile

What does Walden H. Lee inspect?

Walden H. Lee appears on 23 documents on file covering 16 sites, mostly in California.

What do they cite most often?

21 CFR 211.165 (testing and release for distribution), followed by 21 CFR 211.68 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Walden H. Lee is dated Jun 17, 2026.